Literature DB >> 28504026

The influence of time horizon on results of cost-effectiveness analyses.

David D Kim1, Colby L Wilkinson1, Elle F Pope1, James D Chambers1, Joshua T Cohen1, Peter J Neumann1.   

Abstract

BACKGROUND: Debates persist on the appropriate time horizon from a payer's perspective and how the time horizon in cost-effectiveness analysis (CEA) influences the value assessment.
METHODS: We systematically reviewed the Tufts Medical Center CEA Registry and identified US-based studies that used a payer perspective from 2005-2014. We classified the identified CEAs as short-term (time horizon ≤ 5 years) and long-term (> 5 years), and examined associations between study characteristics and the specified time horizon. We also developed case studies with selected interventions to further explore the relationship between time horizon and projected costs, benefits, and incremental cost-effectiveness ratios (ICER).
RESULTS: Among 782 identified studies that met our inclusion criteria, 552 studies (71%) utilized a long-term time horizon while 198 studies (25%) used a short-term horizon. Among studies that employed multiple time horizons, the extension of the time horizon yielded more favorable ICERs in 19 cases and less favorable ICERs in 4 cases. Case studies showed the use of a longer time horizon also yielded more favorable ICERs.
CONCLUSION: The assumed time horizon in CEAs can substantially influence the value assessment of medical interventions. To capture all consequences, we encourage the use of time horizons that extend sufficiently into the future.

Keywords:  Time horizon; cost-effectiveness analysis; health technology assessment; systematic review; value assessment

Mesh:

Year:  2017        PMID: 28504026     DOI: 10.1080/14737167.2017.1331432

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  14 in total

1.  A cost-utility analysis of atezolizumab in the second-line treatment of patients with metastatic bladder cancer.

Authors:  A Parmar; M Richardson; P C Coyte; S Cheng; B Sander; K K W Chan
Journal:  Curr Oncol       Date:  2020-08-01       Impact factor: 3.677

2.  Targeted Incentive Programs For Lung Cancer Screening Can Improve Population Health And Economic Efficiency.

Authors:  David D Kim; Joshua T Cohen; John B Wong; Babak Mohit; A Mark Fendrick; David M Kent; Peter J Neumann
Journal:  Health Aff (Millwood)       Date:  2019-01       Impact factor: 6.301

Review 3.  The cost-effectiveness of treatments for attention deficit-hyperactivity disorder and autism spectrum disorder in children and adolescents: a systematic review.

Authors:  Filipa Sampaio; Inna Feldman; Tara A Lavelle; Norbert Skokauskas
Journal:  Eur Child Adolesc Psychiatry       Date:  2021-03-09       Impact factor: 4.785

Review 4.  Evidence for investing in parenting interventions aiming to improve child health: a systematic review of economic evaluations.

Authors:  Filipa Sampaio; Camilla Nystrand; Inna Feldman; Cathrine Mihalopoulos
Journal:  Eur Child Adolesc Psychiatry       Date:  2022-03-19       Impact factor: 4.785

5.  Cost Effectiveness of Pharmacological Treatments for Asthma: A Systematic Review.

Authors:  Carlos E Rodriguez-Martinez; Monica P Sossa-Briceño; Jose A Castro-Rodriguez
Journal:  Pharmacoeconomics       Date:  2018-10       Impact factor: 4.981

6.  The cost-effectiveness of medication, laser trabeculoplasty, and trabeculectomy for treatment of open-angle glaucoma in South Korea.

Authors:  Jin A Choi; Lina D Song; Seulggie Choi; Sang Min Park; Jin Woo Kwon; Donghyun Jee
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

Review 7.  Principles of pharmacoeconomic analysis: the case of pharmacist-led interventions.

Authors:  Fernanda S Tonin; Ignacio Aznar-Lou; Vasco M Pontinha; Roberto Pontarolo; Fernando Fernandez-Llimos
Journal:  Pharm Pract (Granada)       Date:  2021-02-22

Review 8.  Cost-Effectiveness of Immune Checkpoint Inhibitors in Urothelial Carcinoma-A Review.

Authors:  Arman S Walia; Randy F Sweis; Piyush K Agarwal; Andrew K Kader; Parth K Modi
Journal:  Cancers (Basel)       Date:  2021-12-24       Impact factor: 6.639

9.  Economic evaluations of psychological treatments for common mental disorders in low- and middle-income countries: protocol for a systematic review.

Authors:  Vimbayi Mutyambizi-Mafunda; Bronwyn Myers; Katherine Sorsdahl; Esther Chanakira; Crick Lund; Susan Cleary
Journal:  Glob Health Action       Date:  2021-01-01       Impact factor: 2.640

10.  Model-Based Biomarker Selection for Dose Individualization of Tyrosine-Kinase Inhibitors.

Authors:  Maddalena Centanni; Lena E Friberg
Journal:  Front Pharmacol       Date:  2020-03-12       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.